Compare SCHW & TMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCHW | TMO |
|---|---|---|
| Founded | 1971 | 1956 |
| Country | United States | United States |
| Employees | 33000 | N/A |
| Industry | Investment Bankers/Brokers/Service | Industrial Machinery/Components |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6B | 164.3B |
| IPO Year | N/A | 1996 |
| Metric | SCHW | TMO |
|---|---|---|
| Price | $91.79 | $471.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 18 |
| Target Price | $112.56 | ★ $636.00 |
| AVG Volume (30 Days) | ★ 10.7M | 2.3M |
| Earning Date | 04-16-2026 | 04-23-2026 |
| Dividend Yield | ★ 1.40% | 0.40% |
| EPS Growth | N/A | ★ 7.32 |
| EPS | N/A | ★ 4.43 |
| Revenue | N/A | ★ $20,918,000,000.00 |
| Revenue This Year | $13.87 | $6.55 |
| Revenue Next Year | $9.39 | $5.11 |
| P/E Ratio | ★ $20.51 | $105.95 |
| Revenue Growth | N/A | ★ 14.47 |
| 52 Week Low | $83.96 | $385.46 |
| 52 Week High | $107.50 | $643.99 |
| Indicator | SCHW | TMO |
|---|---|---|
| Relative Strength Index (RSI) | 57.98 | 48.85 |
| Support Level | $89.58 | $456.87 |
| Resistance Level | $93.16 | $481.83 |
| Average True Range (ATR) | 2.11 | 14.39 |
| MACD | 0.55 | 0.53 |
| Stochastic Oscillator | 96.00 | 45.31 |
Charles Schwab is one of the largest retail-oriented financial-services companies in the US, with $11.9 trillion in client assets across its brokerage, banking, asset management, custody, financial advisory, and wealth-management businesses at the end of 2025. While best known for its retail brokerage offering, Schwab generates the lion's share of its revenue and profits through its Charles Schwab Bank and asset management segments. The firm is a dominant player in Registered Investment Advisor(RIA) custody, with over 40% market share, and has recently pushed into wealth management with robo-advisory, direct indexing, and other managed-investment solutions.
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).